Rheumatoid Arthritis

The development of disease-modifying anti-rheumatic drugs (DMARDs) has led to better control of disease activity in patients with rheumatoid arthritis (RA). Patients with RA are living longer. This…

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.  Gender and…

Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity. Despite methotrexate’s near-ubiquitous use in…

In a world where telemedicine and virtual care are not going away, is there value in patients assessing their own tender and swollen joints? Work from the Canadian Early Arthritis Cohort (CATCH, @…

Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis. With…

The first full day of Abstracts and Presentations from ACR Convergence, the 2021 Virtual meeting, was full of highly engaging sessions, quality posters and unique presentations.  To hear more…

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a…

In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical…

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and…